Fexinidazole

Fexinidazole
IUPAC name

1-Methyl-2-{[4-(methylsulfanyl)phenoxy]methyl}-5-nitro-1H-imidazole
Other names

HOE 239
Identifiers
CAS number 59729-37-2
PubChem 68792
ChemSpider 62032
UNII 306ERL82IR
Jmol-3D images Image 1
Properties
Molecular formula C12H13N3O3S
Molar mass 279.31 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Fexinidazole is an antiparasitic agent.[1] It has activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis and Entamoeba histolytica.[1]

Fexinidazole was discovered by the German pharmaceutical company Hoechst AG, but its development as a pharmaceutical was halted in the 1980s.[2] Fexinidazole is now being studied through a collaboration between Sanofi and the Drugs for Neglected Diseases Initiative for the treatment of Chagas disease and human African trypanosomiasis (sleeping sickness).[3][4] Fexinidazole is the first drug candidate for the treatment of advanced-stage sleeping sickness in thirty years.[5]

References

  1. ^ a b Raether, W; Seidenath, H (1983). "The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica". Annals of tropical medicine and parasitology 77 (1): 13–26. PMID 6411009. 
  2. ^ "Jump-Start on Slow Trek to Treatment for a Disease". New York Times. January 8, 2008. http://www.nytimes.com/2008/01/08/health/research/08slee.html. 
  3. ^ "Fexinidazole Progresses into Clinical Development". DNDi Newsletter. November 2009. http://www.dndi.org/newsletters/n17/en/10_1.htm. 
  4. ^ "Sanofi-aventis and DNDi enter into a Collaboration Agreement on a New Drug for Sleeping Sickness, Fexinidazole". DNDi. May 18, 2009. http://www.dndi.org/press-releases/458-sanofi-aventis-and-dndi-enter-into-a-collaboration-agreement-on-a-new-drug-for-sleeping-sickness-fexinidazole.html. 
  5. ^ Torreele, E; Bourdin Trunz, B; Tweats, D; Kaiser, M; Brun, R; Mazué, G; Bray, MA; Pécoul, B (2010). Boelaert, Marleen. ed. "Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness". PLoS neglected tropical diseases 4 (12): e923. doi:10.1371/journal.pntd.0000923. PMC 3006138. PMID 21200426. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3006138.